Sassoferrato, Italy

Laura Amori

This inventor holds 2 USPTO granted patents. Top assignees: Universita Delgi Studi Di Parma, University System of Maryland. Active years: 2016.


% Patents Active = 100.0

Average Co-Inventor Count = 3.0

ph-index = 1


Company Filing History:


Years Active: 2016

Loading Chart...
2 patents (USPTO):Explore Patents

Title: Laura Amori: Innovator in Biochemical Research

Introduction

Laura Amori is a distinguished inventor based in Sassoferrato, Italy. She has made significant contributions to the field of biochemistry, particularly in the development of novel compounds that have potential therapeutic applications. With a total of 2 patents, her work focuses on the inhibition of specific enzymes that play a role in various pathological conditions.

Latest Patents

Amori's latest patents include innovative derivatives of nicotinic acid N-oxide. These compounds are designed to act as inhibitors of the enzyme 3-hydroxyanthranilate-3,4-dioxygenase (3HAO). The patented compounds are chemically stable and have the ability to reduce QUIN biosynthesis in vivo, especially under excitotoxic or pathological conditions. This advancement holds promise for therapeutic interventions in related diseases.

Career Highlights

Throughout her career, Laura Amori has worked with reputable institutions, including the University System of Maryland and Università degli Studi di Parma. Her research has garnered attention for its potential impact on understanding and treating neurological disorders.

Collaborations

Amori has collaborated with notable colleagues such as Robert Schwarcz and Gabriele Costantino. These partnerships have enriched her research and contributed to the advancement of her innovative work.

Conclusion

Laura Amori's contributions to biochemical research and her innovative patents highlight her role as a leading inventor in her field. Her work continues to pave the way for future advancements in therapeutic applications.

Profile summary based on public USPTO records.
Please report any incorrect information to [email protected]
Loading…